資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/32537
|
| 標題: | Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan |
| 作者: | Lee, Ching-Chi
Lee, Chung-Hsun
Chen, Po-Lin
Hsieh, Chih-Chia
Hung-Jen Tang(湯宏仁)
Ko, Wen-Chien |
| 貢獻者: | Chang Jung Christian Univ, Coll Hlth Sci, Grad Inst Med Sci
Tainan Sin Lau Hosp, Dept Adult Crit Care Med
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Emergency Med
Natl Cheng Kung Univ, Coll Med, Dept Med
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med
Chi Mei Med Ctr, Dept Med
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr |
| 關鍵字: | cefazolin
definitive therapy
community
bacteremia
Escherichia coli
Klebsiella pneumoniae
Proteus mirabilis |
| 日期: | 2019 |
| 上傳時間: | 2020-07-29 13:48:57 (UTC+8) |
| 出版者: | MDPI |
| 摘要: | Cefazolin is traditionally active against Escherichia coli, Klebsiella species, and Proteus mirabilis (EKP) isolates. The Clinical and Laboratory Standards Institute (CLSI) has twice updated cefazolin susceptibility breakpoints for EKP since 2010, but its role in the definitive treatment of cefazolin-susceptible EKP bacteremia remains debated. To assess its efficacy as a definitive agent, the 8-year cohort study consisted of 941 adults with monomicrobial cefazolin-susceptible EKP bacteremia, based on the CLSI criteria issued in 2019, was retrospectively established in a medical center. Based on the definitive antimicrobial prescription, eligible patients were categorized into the cefazolin (399 patients, 42.4%) and broader-spectrum antibiotic (BSA) (542, 57.6%) groups. Initially, fewer proportions of patients with fatal comorbidities (the McCabe classification) and the critical illness (a Pitt bacteremia score >= 4) at the onset and day 3 of the bacteremia episode were found in the cefazolin group, compared to the BSA group. After propensity-score matching, no significant difference of patient proportions between the cefazolin (345 patients) and BSA (345) groups was observed, in terms of the elderly, types and severity of comorbidities, bacteremia severity at the onset and day 3, major bacteremia sources, and the 15-day and 30-day crude mortality. In early outcomes, lengths of time to defervescence, intravenous (IV) antimicrobial administration, and hospitalization were similar in the two matched groups; lower costs of IV antimicrobial administration were observed in the cefazolin group. Notably, for late outcomes, lower proportions of post-treatment infections caused by antimicrobial-resistant pathogens (ARPs) and post-treatment mortality rates were evidenced in the cefazolin group. Conclusively, cefazolin is definitively efficacious and cost-effective for adults with community-onset cefazolin-susceptible EKP bacteremia in this one-center study, compared to BSAs. However, a prospective multicenter study should be conducted for external validation with other communities. |
| 關聯: | Antibiotics-Basel, v.8, n.4, 216 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 10.3390-antibiotics8040216.pdf | | 891Kb | Adobe PDF | 288 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1176 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
